This public offering consisted of USD400m 3.25% unsecured senior notes due 1 May 2019 and USD250m 4.75% unsecured senior notes due 1 May 2024.
Proceeds of this offering are expected to be used by the company for general business purposes, funding, in part, the pending acquisition of two biotech medical office buildings in Boston as well as to repay certain mortgage notes.
The joint book-running managers for this offering, which is subject to customary closing conditions, were Citigroup, Jefferies, Morgan Stanley and Wells Fargo Securities.
Perrigo to acquire United States rights for Entocort from AstraZeneca
US FDA approves Boehringer Ingelheim's Pradaxa
Phase II clinical trial for potential treatment of androgenetic alopecia completed by Samumed
Life Sciences Partners collaborates on immuno-oncology with Bristol-Myers Squibb
Arsanis initiates first cohort in Phase one clinical trial of ASN100
Impax introduces generic Avodart (Dutasteride) Capsules, 0.5 mg
Mylan unveils generic FazaClo orally disintegrating tablets for treating schizophrenia